title: [Perspectives for application of heparin derivates in the treatment of patients with pulmonary cancer].
abstract: There is presented a literature review and results of heparin derivates with low molecular mass (HDLMM) application in complex of treatment in 50 patients with the nonsmallcellular pulmonary cancer (NSCPC) stage IIIA, which included conduction of two courses of inductional polychemotherapy (IPCHTH) according to Vp=P scheme with subsequent performance of operative intervention. In patients of the main group a HDLMM named enoxaparine sodium (Clexane, Sanofi-Aventis) was administered in dose 20 mg during 10 days, starting its introduction 3 days before the IPCHTH application. Clexane was also used for thromboembolic complications prophylaxis during performance of operative intervention (in 40 mg daily dosage during 7-12 days). Effect of IPCHTH was achieved in 52% of patients of the main group and in 44% - of the control one. In the main group 17 patients were operated on, of them 12 (70.6%) - radically, in control group - 16, including 10 (62.5%) radically operated. Thromboembolic complications were not observed. After the operation all the patients survived. Under the IPCHTH influence the viable oncocytes level and the tumor proliferative activity have had lowered trustworthily, the therapeutic pathomorphosis degree was higher in patients of the main group than in the control one. So, application of HDLMM in complex of treatment of the NSCPC locally advanced form had promoted improvement of the IPCHTH immediate results, enhancement of quantity of complete or partial response as well as the resectability indexes, did not raise the postoperative complications occurrence risk and mortality.
authors.forename: O A
authors.initials: OA
authors.lastname: Sukhoversha
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D017984:Enoxaparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D009362:Neoplasm Metastasis; D013510:Pulmonary Surgical Procedures; D013923:Thromboembolism / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin